Shares of Hillstream BioPharma, Inc. (NASDAQ:HILS – Get Free Report) traded down 6.1% on Tuesday . The stock traded as low as $2.74 and last traded at $2.77. 109,171 shares changed hands during mid-day trading, a decline of 92% from the average session volume of 1,388,685 shares. The stock had previously closed at $2.95.
Hillstream BioPharma Stock Down 13.2 %
The company’s 50-day moving average is $2.37 and its two-hundred day moving average is $2.44. The company has a market capitalization of $42.78 million, a P/E ratio of -3.89 and a beta of 3.08.
Hillstream BioPharma Company Profile
Hillstream BioPharma, Inc, a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) and targeted immuno-oncology novel biologics for the treatment drug resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors.
Recommended Stories
- Five stocks we like better than Hillstream BioPharma
- High Flyers: 3 Natural Gas Stocks for March 2022
- Gilead’s Stock Surge: What’s Fueling the Momentum?
- How to Capture the Benefits of Dividend Increases
- Breakout Alert: Qualcomm Just Hit The Rally Button
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Mercado Libre Shares Go on Sale: Is Now the Time to Buy?
Receive News & Ratings for Hillstream BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hillstream BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.